基础研究

轴突导向因子受体3缺陷促进化疗药物诱导的巨噬细胞泡沫化进程

  • 刘永 ,
  • 程晓雷 ,
  • 崔香丽 ,
  • 唐颢 ,
  • 陈还珍
展开
  • 1.山西医科大学基础医学院生理学系 (太原 030012 )
    2.南京鼓楼医院 (南京 210008 )
    3.国家心血管病中心华中分中心 (郑州 450003 )
    4.山西医科大学第一医院 (太原 030001 )

收稿日期: 2023-06-29

  网络出版日期: 2024-04-08

基金资助

河南省中青年卫生健康科技创新优秀青年人才培养项目(YXKC2021050)

ROBO3 deficiency promotes chemotherapy⁃induced transition of macrophage to foam cell

  • Yong LIU ,
  • XiaoLei CHENG ,
  • Xiangli CUI ,
  • Hao TANG ,
  • Huanzhen CHEN
Expand
  • Department of Physiology,School of Basic Medicine Sciences,Shanxi Medical University,Taiyuan 030012,China

Received date: 2023-06-29

  Online published: 2024-04-08

摘要

目的 探索化疗药物阿霉素或顺铂对巨噬细胞脂质代谢的影响及调控机制。 方法 阿霉素或者顺铂处理巨噬细胞RAW264.7,用油红O、ELISA等检测细胞内脂质水平;用RNA sequence和Western blot筛选和验证化疗药物处理后的基因表达变化;探讨沉默ROBO3对细胞脂质代谢的影响,并用Q-PCR和Western blot检测脂质代谢关键靶基因的变化。 结果 阿霉素或顺铂可诱发巨噬细胞胆固醇代谢紊乱,加剧巨噬细胞泡沫化。进一步研究显示,轴突导向因子受体ROBO3的表达水平在化疗药物诱导巨噬细胞泡沫化进程中先增高后降低;沉默ROBO3加重oxldl诱导的巨噬细胞泡沫化水平。机制上,ROBO3沉默可上升胆固醇合成相关基因DHCR24表达,抑制胆固醇外排相关基因ABCG1表达,造成巨噬细胞内胆固醇蓄积。 结论 ROBO3在化疗药物诱导巨噬细胞胆固醇代谢紊乱及泡沫化进程中发挥重要调控作用,可为化疗相关动脉粥样硬化的防治提供新的靶点和思路。

本文引用格式

刘永 , 程晓雷 , 崔香丽 , 唐颢 , 陈还珍 . 轴突导向因子受体3缺陷促进化疗药物诱导的巨噬细胞泡沫化进程[J]. 实用医学杂志, 2024 , 40(6) : 787 -795 . DOI: 10.3969/j.issn.1006-5725.2024.06.010

Abstract

Objective To explore the effect of chemotherapeutic drugs doxorubicin or cisplatin on lipid metabolism of macrophages and its regulatory mechanism. Methods Macrophage RAW264.7 was treated with doxorubicin or cisplatin, and intracellular lipid level was detected by oil red O and ELISA; RNA sequence screening and Western blot were used to confirm the changes of gene expression after chemotherapeutic drug treatment; The effects of silencing ROBO3 on cellular lipid metabolism were explored, and changes in key target genes of lipid metabolism were detected by Q-PCR and western blot. Results Adriamycin or cisplatin induced disturbances in macrophage cholesterol metabolism and exacerbated macrophage foaminess. Further studies showed that the expression of the axon guidance factor receptor, ROBO3, increased and then decreased during the chemotherapeutic drug-induced macrophage foaming process. Further intervention with ROBO3 exacerbates oxldl-induced cholesterol accumulation and foam formation in macrophages. Mechanistically, ROBO3 deficiency promotes the expression of cholesterol synthesis-related gene DHCR24 and inhibits the expression of cholesterol elimination-related gene ABCG1, resulting in cholesterol accumulation in macrophages. Conclusion This study found that ROBO3 plays an important regulatory role in the disruption of cholesterol metabolism and its foaming process in macrophages induced by chemotherapeutic drugs, which may provide new targets and ideas for the prevention and treatment of chemotherapy-related atherosclerosis.

参考文献

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021,71(3):209-249. doi:10.3322/caac.21660
2 魏辉,李慧,余国华,等. 白细胞介素-38对ApoE^(-/-)小鼠动脉粥样硬化作用及机制研究[J].实用医学杂志,2021,37(7):858-862.
3 MOSLEHI J J. Cardiovascular Toxic Effects of Targeted Cancer Therapies [J]. N Engl J Med, 2016,375(15):1457-1467. doi:10.1056/nejmra1100265
4 吴军,崔伟燕,李平,等. Life′s Simple 7干预减轻Her?2阳性乳腺癌患者化疗相关心血管系统损害的研究[J]. 实用医学杂志,2023,39(13):1647-1651,1656.
5 HERRMANN J. Vascular toxic effects of cancer therapies [J]. Nat Rev Cardiol, 2020,17(8):503-522. doi:10.1038/s41569-020-0347-2
6 VAN DEN BELT-DUSEBOUT A W, NUVER J, DE WIT R, et al. Long-term risk of cardio vascular disease in 5-year survivors of testicular cancer [J]. J Clin Oncol, 2006, 24(3): 467-475. doi:10.1200/jco.2005.02.7193
7 BOSMAN M, FAVERE K, NEUTEL CHG, et al. Doxorubicin induces arterial stiffness: A comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice [J]. Toxicol Lett, 2021,346:23-33. doi:10.1016/j.toxlet.2021.04.015
8 BOSMAN M, KRUGER D N, FAVERE K, et al. Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity[J]. Int J Mol Sci, 2021,22(23):12812. doi:10.3390/ijms222312812
9 CHEN S G, XIAO J, LIU X H, et al. Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells [J]. Acta Pharmacol Sin, 2010,31(10):1343-1349. doi:10.1038/aps.2010.166
10 YUAN Y, LI P, YE J. Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis [J]. Protein Cell, 2012,3(3):173-181. doi:10.1007/s13238-012-2025-6
11 MOORE K J, SHEED F J, FISHER E A. Macrophages in atherosclerosis: a dynamic balance [J]. Nat Rev Immunol, 2013,13(10):709-721. doi:10.1038/nri3520
12 GONG X, QIAN H, ZHOU X, et al. Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection [J]. Cell, 2016,165(6):1467-1478. doi:10.1016/j.cell.2016.05.022
13 WU N, LI R Q, LI L. SOAT1 deficiency attenuates atherosclerosis by regulating inflammation and cholesterol transportation via HO-1 pathway [J]. Biochem Biophys Res Commun, 2018,501(2):343-350. doi:10.1016/j.bbrc.2018.03.137
14 WATERHAM H R, KOSTER J, ROMEIJN G J, et al. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis [J]. Am J Hum Genet, 2001,69(4):685-694. doi:10.1086/323473
15 YAMAZAKI H, TAKAHASHI M, WAKABAYASHI T, et al. Loss of ACAT1 Attenuates Atherosclerosis Aggravated by Loss of NCEH1 in Bone Marrow-Derived Cells [J]. J Atheroscler Thromb, 2019,26(3):246-259. doi:10.5551/jat.44040
16 OUIMET M, BARRETT T J, FISHER E A. HDL and Reverse Cholesterol Transport [J]. Circ Res, 2019,124(10):1505-1518. doi:10.1161/circresaha.119.312617
17 ZHUANG M, LI X, ZHU J, et al. The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression [J]. Nucleic Acids Res, 2019,47(9):4765-4777. doi:10.1093/nar/gkz157
18 WANG J Q, LIN Z C, LI L L, et al. SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1 [J]. J Biol Chem, 2021,296:100032. doi:10.1074/jbc.ra120.015420
19 WANG J, ZHAO J, YAN C, et al. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial [J]. Cell Metab, 2022,34(5):667-680. doi:10.1016/j.cmet.2022.03.006
20 ORECCHIONI M, KOBIYAMA K, WINKELS H, et al. Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production [J]. Science, 2022,375(6577):214-221. doi:10.1126/science.abg3067
21 ZHANG X, MCDONALD J G, ARYAL B, et al. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis [J]. Proc Natl Acad Sci U S A, 2021,118(47):e2107682118. doi:10.1073/pnas.2107682118
文章导航

/